Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

Devices shown at AI Impact Summit can be deployed across hospitals and resource-scarce settings to improve accuracy and ...

Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma - ...

From bionic eyes to cell and gene therapies in clinical therapies, it's an exciting time for emerging technologies aiming to ...

Natasha, a Charlotte graduate student whose vision limitations made doctors say she would never drive, is now driving.

Health experts warn no single type of product can treat all kinds of eye diseases, refuting false social media advertisements circulating in Malaysia touting a brand of eye drops. They advise patients ...

Eye doctors treating vision-threatening infections in drug users are uniquely positioned to connect patients with life-saving ...

Imran Khan's vision loss has necessitated a move from prison to a specialised hospital for urgent ophthalmic care ...

In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality ...

Humans develop sharp vision during early fetal development thanks to an interplay between a vitamin A derivative and thyroid hormones in the retina, Johns Hopkins University scientists have found. The ...

Discover how tiny, cutting‑edge surgical tools are transforming glaucoma care with a gentler, less invasive approach. Learn why Moran Eye Center experts use MIGS to help protect vision earlier and ...

Piper Sandler & Co. is serving as the sole manager for the Offering. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.